**Poliovirus containment**

FORM 2: Progress reporting form on preparations for poliovirus containment and completion of Phase I of GAPIII

19 September 2018

****

**Contents**

[Abbreviations and Acronyms 3](#_Toc520119888)

[Declarations 4](#_Toc520119889)

[1. NCC’s follow-up on previous RCC recommendations related to poliovirus containment 6](#_Toc520119890)

[List of previous RCC recommendations 6](#_Toc520119891)

[2. Identification and survey of facilities 7](#_Toc520119892)

[List of all facilities in the country/territory 7](#_Toc520119893)

[Facilities surveyed during the current reporting period 8](#_Toc520119894)

[Facilities that do not retain any PV 8](#_Toc520119895)

[3. Retention of poliovirus infectious or potentially infectious material (PV IM or PIM) 9](#_Toc520119896)

[List of facilities retaining WPV/VDPV IM or PIM, and requiring containment 9](#_Toc520119897)

[List of facilities retaining OPV2/Sabin2 IM and requiring containment 10](#_Toc520119898)

[List of facilities retaining OPV1/Sabin1 or OPV3/Sabin3 IM, requiring containment in Phase III of GAPIII 10](#_Toc520119899)

[List of facilities retaining OPV/Sabin PIM 11](#_Toc520119900)

[4. Designation of poliovirus-essential facilities (PEFs) 13](#_Toc520119901)

[List of designated PEFs in the country: 13](#_Toc520119902)

[5. Nomination of the National Authority for Containment (NAC) in countries/territories with designated PEFs 14](#_Toc520119903)

# 

# Abbreviations and Acronyms

CCS GAPIII Containment Certification Scheme

GAPIII Global Action Plan III for Poliovirus Containment

GCC Global Commission for the Certification of the Eradication of Poliomyelitis

IM Infectious material

MoH Ministry of Health

NAC National authority for containment

NCC National Certification Committee for Poliomyelitis Eradication

NPCC National Poliovirus Containment Coordinator

NTFC National Task Force for Containment

OPV Oral polio vaccine

bOPV Bivalent oral polio vaccine (containing attenuated Sabin poliovirus type 1 and type 3)

mOPV Monovalent oral polio vaccine (containing one type of attenuated Sabin poliovirus)

mOPV1 Monovalent oral polio vaccine type 1

mOPV2 Monovalent oral polio vaccine type 2

mOPV3 Monovalent oral polio vaccine type 3

OPV1 Oral polio vaccine type 1

OPV2 Oral polio vaccine type 2

OPV3 Oral polio vaccine type 3

tOPV Trivalent oral polio vaccine (containing attenuated Sabin poliovirus type 1, type 2 and type 3)

PEF Poliovirus-essential facility

PIM Potentially infectious material

PV Poliovirus

PV1 Poliovirus type 1

PV2 Poliovirus type 2

PV3 Poliovirus type 3

VDPV Vaccine-derived poliovirus

VDPV1 Vaccine-derived poliovirus type 1

VDPV2 Vaccine-derived poliovirus type 2

VDPV3 Vaccine-derived poliovirus type 3

WHO World Health Organization

WPV Wild poliovirus

WPV1 Wild poliovirus type 1

WPV2 Wild poliovirus type 2

WPV3 Wild Poliovirus type 3

# Declarations

National Poliovirus Containment coordinators (NPCCs), National Task Force for Containment (NTFCs), or other identified focal points, as appropriate, are expected to complete this form annually and deliver it to the Chair of the National Certification Committee for Poliomyelitis Eradication (NCC) in support of the finalization of national reports.

Details of the person[[1]](#footnote-1) submitting this form to the NCC Chair:

|  |  |
| --- | --- |
| Name: |  |
| Designation: | NPCC  NTF Chair  Other  If other, please specify: |
| Data provided refer to country/territory: |  |
| E-mail: |  |
| Reporting period: |  |
| Signature: |  |
| Date of submission to the NCC Chair: |  |

With the publication of the new *WHO Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses* ([PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), 10 April 2018), the Global Certification Commission for the Eradication of Poliomyelitis (GCC) requests:

1. The establishment of a standardized data collection and verification mechanism;
2. NCC/RCC reports to clearly indicate where and when activities in Phase I have been completed, based on a standardized data collection and verification mechanism, so that, on the basis of equivalent data quality between regions, the GCC can declare global completion of Phase I;
3. The completion of Phase I for all type 2 poliovirus (PV2) within one year of its publication (by 10 April 2019);
4. Countries affected by ongoing transmission of cVDPV2 to repeat their inventories and destroy, transfer or contain PV2 materials after the outbreak is declared closed;
5. RCCs to urge countries to complete the identification, destruction, transfer or containment (Phase I of [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/)) of WPV1 and WPV3 materials by the end of Phase II of [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/). Phase II ends with GCC’s declaration of global eradication of poliomyelitis;
6. Countries planning to designate facilities for the retention of WPV1 and WPV3 materials to weigh the risks and benefits of having such facilities and the commitments that will be required to comply with the primary (facility), secondary (population immunity) and tertiary (sanitation and hygiene) safeguards.

**NOTE[[2]](#footnote-2)**: A facility is defined as any site (e.g. laboratory, repository or vaccine production unit) owned or operated by any level of government, academic institution, corporation, company, partnership, society, association, firm, sole proprietorship or other legal entity.

Details of the NCC Chair:

|  |  |
| --- | --- |
| Name: |  |
| Designation: | NCC Chair |
| Country: |  |
| E-mail: |  |
| Reporting period: |  |
| I, the NCC Chair, declare that all sections in this form are completed: | Yes  No  If no, please explain[[3]](#footnote-3): |
| Signature: |  |
| Date: |  |

# 1. NCC’s follow-up on previous RCC recommendations related to poliovirus containment

## List of previous RCC recommendations

|  |  |  |  |
| --- | --- | --- | --- |
| N° | Previous RCC recommendation(s)[[4]](#footnote-4) related to poliovirus containment in the country/territory | Date of issuance (dd/mm/yyyy) | Follow-up action taken to address RCC recommendation(s) |
| 1. |  |  |  |
| 2. |  |  |  |
| 3. |  |  |  |

Please add rows as necessary

# 2. Identification and survey of facilities

## List of all facilities in the country/territory

|  |  |  |
| --- | --- | --- |
| A current, exhaustive and comprehensive list of **all** facilities in the country/territory is established and available: | | Yes  No  Other  If other, please specify: |
| If **yes**, how many facilities in total are there in the country/territory? | |  |
| If **no**: | By when is the comprehensive list of facilities expected to be completed? | Expected date: |
| By whom is the comprehensive list of facilities expected to be completed? |  |

**NOTE 1[[5]](#footnote-5)**: GCC set the deadline for completion of Phase I for all PV2 at one year after the publication of the *Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses* (i.e. by 10 April 2019), and for WPV1 & WPV3 before the global declaration of WPV eradication.

**NOTE 24**: GCC requested RCCs to urge countries to complete the identification, destruction, transfer or containment (Phase I) of WPV1 and WPV3 materials by the end of Phase II.

**NOTE 34**: GCC recommended that at the time of WPV eradication, all facilities retaining WPVs should have a certificate of containment (CC), and if not, have a time-limited interim certificate of containment (ICC), with a clear end point for obtaining a CC agreed with the GCC.

**NOTE 4[[6]](#footnote-6)**:Certification of WPV eradication should only occur when all WPV materials, in facilities designated for retaining them, are safely and securely contained.

## Facilities surveyed during the current reporting period

|  |  |
| --- | --- |
| Reporting period (dd/mm/yyyy – dd/mm/yyyy): |  |
| FORM 1[[7]](#footnote-7) (or an equivalent questionnaire) has been supplied to **all** facilities in the country/territory: | Yes  No  Other  If other, please specify: |
| N° of facilities that received FORM 1 (or an equivalent questionnaire): |  |
| N° of complete responses obtained from these facilities: |  |
| N° of facilities that sent in an incomplete response: |  |
| N° of facilities that did not respond: |  |
| PV types addressed in this reporting period: | PV1  PV2  PV3 |

## Facilities that do not retain any PV

A detailed list of facilities that never possessed, destroyed, inactivated or transferred to a PEF their poliovirus infectious or potentially infectious materials (PV IM or PIM) should be maintained as a national inventory and be made available to the RCC upon request.

|  |  |
| --- | --- |
| N° of facilities that never had any PV IM or PIM: |  |
| N° of facilities that have destroyed, inactivated or transferred to a PEF all their PV IM or PIM: |  |
| Total N° of facilities that **do not retain** any PV IM or PIM: |  |

# 3. Retention of poliovirus infectious or potentially infectious material (PV IM or PIM)

The retention of WPV/VDPV IM, WPV/VDPV PIM, or OPV/Sabin IM is subject to the approval of the responsible national authority (e.g. MoH) and to the certified implementation of containment requirements following timelines described in [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/). National authorities (e.g. MoH) of countries retaining such materials for critical functions must:

1. Approve the retention of PV materials requiring containment, i.e. WPV/VDPV IM, WPV/VDPV PIM, or OPV/Sabin IM.
2. Designate as poliovirus-essential (PEFs) those facilities where such materials are/will be retained.
3. Nominate a national authority for containment (NAC) responsible for the containment certification of designated PEFs against [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), following [CCS](http://polioeradication.org/wp-content/uploads/2017/03/CCS_19022017-EN.pdf).

Facilities retaining OPV/Sabin PIM must declare this to their national authorities (e.g. MoH) and are encouraged to follow the WHO recommendations for the safe retention and handling of these materials provided in the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/)*.*

## List of facilities retaining WPV/VDPV IM or PIM, and requiring containment

WPV2 was declared eradicated in September 2015. Please provide complete data on the identification of WPV2/VDPV2 IM, and ensure that complete data on the identification and retention of WPV2/VDPV2 PIM are provided **within 1 year of** the publication of the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/) (i.e. by 10 April 2019). In countries that experienced VDPV2 circulation and the use of mOPV2 for outbreak response purposes after the switch from tOPV to bOPV, the collection of data on OPV2/Sabin2 IM or PIM will only be completed after the last use of mOPV2.

The collection of data on the identification and retention of WPV1/VDPV1 IM or PIM and WPV3/VDPV3 IM or PIM has started. Please ensure that complete data for WPV1/WPV3 IM or PIM are provided before the global declaration of WPV eradication. As the use of bOPV and/or mOPV1/mOPV3 will continue beyond the global declaration of WPV eradication, VDPV1/VDPV3 are expected to continue to circulate. For this reason, the collection of data on VDPV1/VDPV3 IM or PIM will only be completed after the last use of bOPV and/or mOPV1/mOPV3.

| N° | Facility name and address | WPV/VDPV | Type of material |
| --- | --- | --- | --- |
| 1. |  | WPV1/VDPV1 | IM |
| PIM |
| WPV2/VDPV2 | IM |
| PIM |
| WPV3/VDPV3 | IM |
| PIM |
| 2. |  | WPV1/VDPV1 | IM |
| PIM |
| WPV2/VDPV2 | IM |
| PIM |
| WPV3/VDPV3 | IM |
| PIM |
| 3. |  | WPV1/VDPV1 | IM |
| PIM |
| WPV2/VDPV2 | IM |
| PIM |
| WPV3/VDPV3 | IM |
| PIM |

Please add rows as needed.

## List of facilities retaining OPV2/Sabin2 IM and requiring containment

Please provide complete data on the identification and retention of OPV2/Sabin2 IM. In countries that experienced VDPV2 circulation and the use of mOPV2 for outbreak response purposes after the switch from tOPV to bOPV, the collection of data on OPV2/Sabin2 IM will only be completed after the last use of mOPV2.

|  |  |  |
| --- | --- | --- |
| N° | Facility name and address | OPV/Sabin IM |
| 1. |  | mOPV2 |
| tOPV |
| Sabin2 |
| 2. |  | mOPV2 |
| tOPV |
| Sabin2 |
| 3. |  | mOPV2 |
| tOPV |
| Sabin2 |

Please add rows as needed

## List of facilities retaining OPV1/Sabin1 or OPV3/Sabin3 IM[[8]](#footnote-8), requiring containment in Phase III of GAPIII

The collection of data on OPV1/Sabin1 and OPV3/Sabin3 IM has started. However, as the use of bOPV and/or mOPV1/mOPV3 will continue beyond the global eradication of WPV eradication, OPV1/Sabin1 and OPV3/Sabin3 strains are expected to continue to circulate, and the collection of data on OPV1/Sabin1 and OPV3/Sabin3 IM will only be completed after the last use of bOPV and/or mOPV1/mOPV3.

|  |  |  |
| --- | --- | --- |
| N° | Facility name and address | OPV1/Sabin1 or OPV3/Sabin3 IM |
| 1. |  | mOPV1 |
| mOPV3 |
| Sabin1 |
| Sabin3 |
| bOPV |
| 2. |  | mOPV1 |
| mOPV3 |
| Sabin1 |
| Sabin3 |
| bOPV |
| 3. |  | mOPV1 |
| mOPV3 |
| Sabin1 |
| Sabin3 |
| bOPV |

Please add rows as needed

## List of facilities retaining OPV/Sabin PIM

Please ensure that complete data on the identification and retention of OPV2/Sabin2 PIM are provided **within 1 year of** the publication of the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/) (i.e. by 10 April 2019). In countries that experienced VDPV2 circulation and the use of mOPV2 for outbreak response purposes after the switch from tOPV to bOPV, the collection of data on OPV2/Sabin2 PIM will only be completed after the last use of mOPV2.

In countries that experienced the use of bOPV, and/or VDPV1/VDPV3 circulation and the use of mOPV1/mOPV3 for outbreak response purposes after the switch from tOPV to bOPV, the collection of data on OPV1/Sabin1 and/or OPV3/Sabin3 PIM will only be completed after the last use of bOPV, mOPV1 and/or mOPV3, respectively.

|  |  |  |
| --- | --- | --- |
| N° | Facility name and address | OPV/Sabin PIM |
| 1. |  | OPV1/Sabin1 |
| OPV2/Sabin2 |
| OPV3/Sabin3 |
| 2. |  | OPV1/Sabin1 |
| OPV2/Sabin2 |
| OPV3/Sabin3 |
| 3. |  | OPV1/Sabin1 |
| OPV2/Sabin2 |
| OPV3/Sabin3 |

Please add rows as needed

# 4. Designation of poliovirus-essential facilities (PEFs)

The retention of WPV/VDPV IM, WPV/VDPV PIM, or OPV/Sabin IM is subject to the approval of the responsible national authority (e.g. MoH) and to the facility’s implementation of containment requirements described in [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), assessed and certified by the national authority for containment (NAC) and GCC, following [CCS](http://polioeradication.org/wp-content/uploads/2017/03/CCS_19022017-EN.pdf).

|  |  |
| --- | --- |
| Are there any national plans for the designation of PEFs in the country/territory? | Yes  No  Other  If other, please specify: |
| Expected total n° of designated PEFs in the country/territory (for all PV types): |  |

## List of designated PEFs in the country:

|  |  |  |
| --- | --- | --- |
| N° | Facility name and address | Date of designation (dd/mm/yyyy) |
| 1. |  |  |
| 2. |  |  |
| 3. |  |  |

Please add rows as needed.

# 5. Nomination of the National Authority for Containment (NAC) in countries/territories with designated PEFs

Countries retaining or planning to retain polioviruses requiring appropriate containment need to nominate the NAC for the containment assessment and certification of designated PEFs against GAPIII. Please provide the list of NAC members.

|  |  |  |
| --- | --- | --- |
|  | Members | Date of nomination (dd/mm/yyyy) |
| 1. |  |  |
| 2. |  |  |
| 3. |  |  |
| 4. |  |  |
| 5. |  |  |
| 6. |  |  |
| 7. |  |  |
| 8. |  |  |
| 9. |  |  |
| 10. |  |  |

Please add rows as needed

1. NPCC/NTFC Chair/Other [↑](#footnote-ref-1)
2. Containment Certification Scheme to support the WHO Global Action Plan for Poliovirus Containment ([CCS](http://polioeradication.org/wp-content/uploads/2017/03/CCS_19022017-EN.pdf)) [↑](#footnote-ref-2)
3. E.g. data on the retention of OPV1/Sabin1, OPV3/Sabin3 and bOPV will only be collected after the last use of bOPV and mOPV1/mOPV3 [↑](#footnote-ref-3)
4. Previous RCC recommendations related to poliovirus containment may be obtained from the NCC Chair [↑](#footnote-ref-4)
5. Report of the special meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis on poliovirus containment, Geneva, Switzerland, 23-25 October 2017 (<http://polioeradication.org/wp-content/uploads/2018/03/polio-global-certification-commission-report-2017-10-20180314-en.pdf>) [↑](#footnote-ref-5)
6. Report from the Seventeenth Meeting Global Commission for the Certification of the Eradication of Poliomyelitis, Geneva, Switzerland, 26-27 February 2018 (<http://polioeradication.org/wp-content/uploads/2018/04/polio-eradication-certification-17th-meeting-global-commission-for-certification-of-poliomyelitis-eradication-20180412.pdf>) [↑](#footnote-ref-6)
7. FORM 1: Facility reporting form (link) [↑](#footnote-ref-7)
8. In countries using bOPV and/or mOPV1/mOPV3, the collection of these data may only be requested after the last use of these vaccines. [↑](#footnote-ref-8)